Approval · Notice of Compliance 28964 · 2022
APRESOLINE: Notice of Compliance 28964
Issued September 15, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28964
- Date
- September 15, 2022
- Company
- Sterimax Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Conversion of the Product Monograph to the 2020 format Revision to the Package Insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APRESOLINE | Not yet assigned | — |
Medicinal ingredients
- HYDRALAZINE HCL 20 MG per ML